Brind.

Alnylam Pharmaceuticals signed a license and research agreement with Scenic Biotech for RNAi therapeutics.

1 report, 1 independent Updated Aug 26

AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.

What happened

Some supportReported by 1 outlet

Who's involved

What this event is mainly about

Alnylam Pharmaceuticals

Keep exploring

The entities involved

Alnylam Pharmaceuticals
biopharmaceutical company
- AstraZeneca's trial failure has created a competitive advantage for Alnylam Pharmaceuticals, which is leveraging AI in its commercial execution.Mon 11:04
- Alnylam Pharmaceuticals, SEC, Truist Financial, and Nasdaq were involved in insider trading disclosures, analyst ratings, and stock trading on June 6, 2026.Sun 17:03

Related events

Alnylam Pharmaceuticals announced new partnerships with AstraZeneca for drug development and with Ionis Pharmaceuticals for clinical trials.Aug 28

Coverage

Newest first; wire copies grouped

Aug 26GlobeNewswireScenic Enters License and Research Agreement with Alnylam Amsterdam, the Netherlands, August 26, 2025 – Scenic Biotech, a pioneer in modifier therapies for severe diseases, today announced a license